AnimaBiotech

@AnimaBiotech

We are advancing Translation Control Therapeutics, the first platform for discovery of small molecule drugs controlling mRNA translation to treat many diseases.

Vrijeme pridruživanja: prosinac 2018.

Tweetovi

Blokirali ste korisnika/cu @AnimaBiotech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AnimaBiotech

  1. 4. velj

    Today marks the 20th anniversary of ! At Anima, we're proud to help advance by working to discover small molecules that can inhibit the translation of the C-Myc . Learn more:

    Poništi
  2. 3. velj

    Come see Co-founder & CEO Yochi Slonim present information about the various applications of our platform & join fellow experts for a panel discussion during the Congress. For more info click here:

    Poništi
  3. 21. sij

    fibrosis, or excessive connective tissue, caused by the over-production of Collagen Type I, can affect any organ? At Anima, we're developing compounds that are able to reduce the production of to prevent . Learn more here:

    Poništi
  4. 16. sij

    Take a look inside our screening platform to understand how we're able to use light pulses to find novel that regulate selectively. Learn more here:

    Poništi
  5. 13. sij

    Don't miss our CEO & co-founder Yochi Slonim's presentation today on our platform at 's in ! For more information click here:

    Poništi
  6. 9. sij

    Transfer RNA or molecules are what interact with mRNA & bring the correct amino acid to the , the translation machinery responsible for turning into a protein? tRNA is at the core of our breakthrough biology platform. Learn more:

    Poništi
  7. 6. sij

    Our has a brand new look! Learn more about our , and by checking it out for yourself here:

    Poništi
  8. 30. pro 2019.

    At Anima, we're proud to be on the cutting edge of & provide an innovative strategy to solve difficult-to-treat diseases with our platform that broadens the scope of drug discovery. Read our media coverage here:

    Poništi
  9. 26. pro 2019.

    not all are the same? There are many ribosome accessory proteins that help with recognition & determine the rate of . At Anima, we're discovering new that target these regulatory proteins. Learn more:

    Poništi
  10. 23. pro 2019.

    At Anima, we're developing an internal across multiple therapeutic areas with high unmet need & hard to treat diseases. These include targeting proteins C-Myc & Huntingtin with translation inhibitors. Learn more here:

    Poništi
  11. 16. pro 2019.

    a disease is considered undruggable when it is difficult or impossible to develop a drug that targets proteins using known development methods? At Anima, our platform finds that can control protein synthesis . Learn more:

    Poništi
  12. 12. pro 2019.

    At Anima, our platform generates millions of light pulse images enabling us to see how much of a target is being made & gain new insights into disease biology by visually tracking . Learn more here:

    Poništi
  13. 10. pro 2019.

    Cells have multiple mechanisms to regulate  transcripts?  binding proteins are one type of RNA-modifying protein that are targeted by our small molecules to control

    Poništi
  14. proslijedio/la je Tweet

    We absolutely loved Yochi Slonim's (Co-Founder & CEO at ) talk on 'Translation Control Therapeutics: Discovery of Small Molecule Drugs that Specifically Control mRNA Translation into Proteins' at this year's RNA Summit!

    Poništi
  15. 4. pro 2019.

    Our CEO & cofounder Yochi Slonim is excited to be in Boston to present our platform and join fellow experts for a panel discussion at the 2nd RNA-Targeted Drug Discovery Summit! Learn more here:

    Poništi
  16. 2. pro 2019.

    Using our platform, we are bypassing traditional drug discovery methods to find & develop drugs that selectively control . Learn more here:

    Poništi
  17. 27. stu 2019.

    We're working to limit off target of drugs by discovering that are in their efficacy. Our approach is proven to find compounds selective in their activity and more versatile. Learn more:

    Poništi
  18. 26. stu 2019.

    At Anima Biotech, we're screening for drugs that can decrease or increase the production of target proteins . Learn more about how we do this here:

    Poništi
  19. 21. stu 2019.

    Interested in learning more about our scientific collaborations? At Anima, we've performed ground-breaking with at , & . Check out the research articles from those collaborations here:

    Poništi
  20. 18. stu 2019.

    This week we’re excited to announce our CEO and cofounder Yochi Slonim is presenting our technology at the 6th China Healthcare Summit hosted by & BayHelix in Shanghai. Learn more about our platform here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·